PhRMA and NOF report finds America’s biopharmaceutical companies are advancing the treatment of osteoporosis with nine medicines in development.
New PhRMA Report: Medicines in development offer hope for osteoporosis patients and families.
Americans are living longer lives, and our aging population is growing. That’s exciting news – but that also means more and more Americans are at risk of a broken bone as a result of osteoporosis or low bone mass. In fact, each year, 2 million broken bones are attributed to osteoporosis and that number is expected to increase to 3 million broken bones a year by 2025.
Fortunately, a new report, “Medicines in Development for Osteoporosis,” provides hope for the nearly 54 million Americans who are living with osteoporosis or low bone mass.
According to the report released today by PhRMA and the National Osteoporosis Foundation (NOF), America’s biopharmaceutical research companies are working to advance the treatment of osteoporosis with nine medicines in development.
These medicines in development use novel approaches to treating the disease and include:
The report found that all of these medicines currently in development are either in clinical trials or undergoing regulatory review by the Food and Drug Administration. And there are 34 clinical trials ongoing across the United States studying osteoporosis treatments.
New innovations by biopharmaceutical companies mark continued progress toward developing treatments for Americans living with osteoporosis or low bone mass. That progress, together with fracture prevention efforts led by NOF, are giving hope to osteoporosis patients for brighter futures.
View the full report here: http://phrma.org/sites/default/files/pdf/medicines-in-development-report-osteoporosis.pdf
